サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：患者腫瘍組織移植モデルの世界市場－規模・シェア・動向分析：腫瘍タイプ別（肺、膵臓）、モデルタイプ別（ラット、マウス）、エンドユーザー別（医薬品およびバイオ医薬品企業、CRO、CDMO）、セグメント予測（2022年～2030年）
市場調査レポート
商品コード
1171007

患者腫瘍組織移植モデルの世界市場－規模・シェア・動向分析：腫瘍タイプ別（肺、膵臓）、モデルタイプ別（ラット、マウス）、エンドユーザー別（医薬品およびバイオ医薬品企業、CRO、CDMO）、セグメント予測（2022年～2030年）

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung, Pancreatic), By Model Type (Rats, Mice), By End-user (Pharma & Biopharma Companies, CROs, CDMOs), And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 275 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
患者腫瘍組織移植モデルの世界市場－規模・シェア・動向分析：腫瘍タイプ別（肺、膵臓）、モデルタイプ別（ラット、マウス）、エンドユーザー別（医薬品およびバイオ医薬品企業、CRO、CDMO）、セグメント予測（2022年～2030年）
出版日: 2022年11月16日
発行: Grand View Research
ページ情報: 英文 275 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の吸入・経鼻製品受託製造サービスプロバイダーの市場規模は、2022年から2030年までに12.8%のCAGRで成長し、2030年に6億6,140万米ドルに達すると予測されています。

新しい治療オプションの需要を促進しているがんの増大、世界の個別化治療の大きな需要は、市場の成長を促進しています。

当レポートでは、世界の患者腫瘍組織移植モデル市場について調査しており、市場展望、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • 腫瘍タイプ
    • モデルタイプ
    • エンドユーザー
    • 地域範囲
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 2次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析（モデル1）
    • 数量価格分析（モデル2）
  • 2次情報リスト
  • 1次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場の展望

第3章 患者腫瘍組織移植モデル市場の変数、動向、範囲

  • 市場系列の展望
    • 親会社の市場展望
    • 関連/補助的な市場の展望
  • 浸透と成長の展望のマッピング
  • 市場力学
    • 市場促進要因分析
      • 世界中で増え続けるがん
      • がんの研究開発投資の増加
      • 個別化治療に対する世界的な需要
    • 市場抑制要因分析
      • 個別化治療のPDXモデルの高コスト
      • 動物モデルの使用に対する厳しい規制
    • 浸透と成長の展望のマッピング
    • COVID-19の影響と回復の分析
    • 主要取引と戦略的提携分析
    • 業界分析－ポーターのファイブフォース分析
    • PESTLE分析

第4章 患者腫瘍組織移植モデル市場：腫瘍タイプセグメント分析

  • 患者腫瘍組織移植モデル市場：定義と範囲
  • 患者腫瘍組織移植モデル市場：腫瘍タイプの市場シェア分析（2021年および2030年）
    • 肺がん
    • 膵臓がん
    • 前立腺がん
    • 乳がん
    • その他のがん

第5章 患者腫瘍組織移植モデル市場：モデルタイプセグメント分析

  • 患者腫瘍組織移植モデル市場：定義と範囲
  • 患者腫瘍組織移植モデル市場：モデルタイプの市場シェア分析（2021年および2030年）
    • マウス
    • ラット

第6章 患者腫瘍組織移植モデル市場：エンドユーザーセグメント分析

  • 患者腫瘍組織移植モデル市場：定義と範囲
  • 患者腫瘍組織移植モデル市場：エンドユーザーの市場シェア分析（2021年および2030年）
    • 医薬品およびバイオ医薬品企業
    • 学術・研究機関
    • CRO・CDMO

第7章 患者腫瘍組織移植モデル市場：地域分析

  • 患者腫瘍組織移植モデル：地域の市場シェア分析（2021年および2030年）
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
      • スペインの患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
    • フランス
      • フランスの患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
  • アジア太平洋地域
    • アジア太平洋地域の患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
    • 中国
    • インド
      • インドの患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
    • 日本
      • 日本の患者腫瘍組織移植モデル市場、2018年～2030年（USD Million）
    • オーストラリア
      • オーストラリアの患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
  • ラテンアメリカ
    • ラテンアメリカの患者腫瘍組織移植モデル市場（100万米ドル）（2018年～2030年）
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • 南アラビア
    • アラブ首長国連邦

第8章 競合情勢

  • 患者腫瘍組織移植モデル：企業市場シェア分析（2021年および2030年）
  • 企業プロファイル
    • Charles River Laboratories
    • The Jackson Laboratory
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • WuxiAppTec
    • Oncodesign
    • Hera Biolabs
    • XenTech
    • Abnova Corporation
図表

List of Tables

  • Table 1 List of Secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Patient-derived xenograft model market snapshot (2021)
  • Fig. 10 Patient-derived xenograft model market segmentation
  • Fig. 11 Heat map analysis
  • Fig. 12 Parent market outlook
  • Fig. 13 Ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 19 Patient-derived xenograft model market tumor type outlook: Segment dashboard
  • Fig. 20 Patient-derived xenograft model market: tumor type movement analysis
  • Fig. 21 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Pancreatic cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 24 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 26 Patient-derived xenograft model market model type outlook: Segment dashboard
  • Fig. 27 Patient-derived xenograft model market: model type movement analysis
  • Fig. 28 Mice market, 2018 - 2030 (USD Million)
  • Fig. 29 Rats market, 2018 - 2030 (USD Million)
  • Fig. 30 Patient-derived xenograft model market end-user outlook: Segment dashboard
  • Fig. 31 Patient-derived xenograft model market: End user movement analysis
  • Fig. 32 Pharmaceutical & Biopharmaceutical companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 34 CROs & CDMOs market, 2018 - 2030 (USD Million)
  • Fig. 35 Regional market: Key takeaways
  • Fig. 36 Patient-derived xenograft model market: Regional movement analysis
  • Fig. 37 North America. market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe market, 2018 - 2030 (USD Million)
  • Fig. 41 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany market, 2018 - 2030 (USD Million)
  • Fig. 43 France market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market, 2018 - 2030 (USD Million)
  • Fig. 48 China market, 2018 - 2030 (USD Million)
  • Fig. 49 India market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 55 MEA market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-002-0

Patient-derived Xenograft Model Market Growth & Trends:

The global patient-derived xenograft model market size is expected to reach USD 661.4 million by 2030, registering a CAGR of 12.8% over the forecast years according to a new report by Grand View Research, Inc. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as "Avatar models"-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

Patient-derived Xenograft Model Market Report Highlights:

  • The breast cancer segment dominated the industry in 2021 due to arise in the cases of breast cancer driving the growth of the market
  • For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed
  • The mice model type segment held the highest revenue share in 2021 due to factors, such as the increasing use of the mice model for cancer treatment and ease of manipulation & procurement
  • The CROs & CDMOs end-user segment accounted for the largest share in 2021. The segment is also anticipated to witness the fastestCAGRover the forecast period
  • A growing number of pharmaceutical companies are outsourcing their preclinical studies to CROs & CDMOs, which, in turn, is driving the growth of this segment
  • North America was the largest region in 2021 due to a high number of research studies in the region, increased funding for preclinical research, and demand for innovative therapies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Tumor Type
    • 1.1.2. Model Type
    • 1.1.3. End User
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Patient-Derived Xenograft Model Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Growing burden of cancer across the globe
      • 3.3.1.2. Increasing R&D investment for cancer research
      • 3.3.1.3. Demand for personalized therapies worldwide
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost of personalized PDX models
      • 3.3.2.2. Stringent regulations towards the use of animal models
    • 3.3.3. Penetration & Growth Prospect Mapping
    • 3.3.4. Covid-19 Impact & Recovery Analysis
    • 3.3.5. Major Deals and Strategic Alliances Analysis
    • 3.3.6. Industry Analysis - Porter's
    • 3.3.7. PESTLE Analysis

Chapter 4. Patient-Derived Xenograft Model Market: Tumor Type Segment Analysis

  • 4.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 4.2. Patient-Derived Xenograft Model Market: Tumor Type Market Share Analysis, 2021 & 2030
    • 4.2.1. Lung Cancer
      • 4.2.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.2. Pancreatic Cancer
      • 4.2.2.1. Pancreatic Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.3. Prostate Cancer
      • 4.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.4. Breast Cancer
      • 4.2.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.5. Other Cancer
      • 4.2.5.1. Other Cancer Market, 2018 - 2030 (USD Million)

Chapter 5. Patient-Derived Xenograft Model Market: Model Type Segment Analysis

  • 5.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 5.2. Patient-Derived Xenograft Model Market: Model Type Market Share Analysis, 2021 & 2030
    • 5.2.1. Mice
      • 5.2.1.1. Mice Market, 2018 - 2030 (USD Million)
    • 5.2.2. Rats
      • 5.2.2.1. Rats Market, 2018 - 2030 (USD Million)

Chapter 6. Patient-Derived Xenograft Model Market: End-user Segment Analysis

  • 6.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 6.2. Patient-Derived Xenograft Model Market: End User Market Share Analysis, 2021 & 2030
    • 6.2.1. Pharmaceutical & Biopharmaceutical Companies
      • 6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
    • 6.2.2. Academic & Research Institutes
      • 6.2.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.2.3. CROs & CDMOs
      • 6.2.3.1. CROs & CDMOs Market, 2018 - 2030 (USD Million)

Chapter 7. Patient-Derived Xenograft Model Market: Regional Analysis

  • 7.1. Patient-Derived Xenograft Model: Regional market share analysis, 2021 & 2030
  • 7.2. North America
    • 7.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.4. Italy
      • 7.3.4.1. Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.5. Spain
      • 7.3.5.1. Spain Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.3.6. France
      • 7.3.6.1. France Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.4.3. India
      • 7.4.3.1. India Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.3. South Arabia
      • 7.6.3.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Patient-Derived Xenograft Model: Company market share analysis, 2021 & 2030
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. The Jackson Laboratory
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Crown Bioscience
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Altogen Labs
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Envigo
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. WuxiAppTec
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Oncodesign
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hera Biolabs
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. XenTech
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Abnova Corporation
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives